Analytical and Pharmacokinetics Core

分析和药代动力学核心

• 批准号: 8381542
• 负责人: WILLIAM C ZAMBONI
• 金额: $ 7.83万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8381542
• 关键词: Affect; Antineoplastic Agents; Biological Assay; Camptothecin Analogue; Cancer Center; Carboplatin; Cisplatin; Complex; Doctor of Philosophy; Drug Kinetics; Electrospray Ionization; Encapsulated; Excision; Extracellular Fluid; Liposomes; Liquid Chromatography; Mass Spectrum Analysis; Methods; Microdialysis; Nanotechnology; Peripheral Blood Mononuclear Cell; Pharmaceutical Preparations; Pharmacodynamics; Pharmacogenetics; Pharmacy Schools; Phase; Plasma; Platinum; Pre-Clinical Model; Process; Research; Resolution; Reticuloendothelial System; Sampling; Schedule; Site; Small Interfering RNA; Solid; Solid Neoplasm; Taxane Compound; Technology; Tumor Tissue; analog; cancer therapy; clinically relevant; docetaxel; drug development; experience; interest; mass spectrometer; nanoparticle; nanosystems; oncology; professor; taxane; translational study; tumor; uptake

Core 1: Analytical and Pharmacokinetics Core PI: William Zamboni, Pharm. D., Ph.D. William Zamboni is an Associate Professor in the Eshelman School of Pharmacy. He is the Director of GLP Analytical Facility, Center for Experimental Therapeufics and the Director of the Translational Oncology and Nanoparticle Drug Development Inifiafive (T0ND2I) Lab at UNC. He has been involved in translational studies of anticancer agents for several years. His research interests focus on the application of pharmacokinetic, pharmacodynamic, and pharmacogenetic principles in the optimizafion of the chemotherapeufic treatment of cancer. He is also developing nanosomal and nanoparticle anticancer agents and evaluating the relafionship between the disposition of these agents and the reticuloendothelial system. As part of these studies, he has used microdialysis to evaluate the tumor extracellular fluid disposition of anticancer agents and factors affecting the delivery and removal of anticancer agents. He has also developed methods and technologies to differentiate between the inactive-encapsulate and active-release forms of the drugs and are evaluafing potential phenotypic probes from the pharmacokinetic and pharmacodynamic disposition of nanosomal and nanoparticles. The clinical relevance of studies is underscored by the need to treat solid tumors with anticancer agents that have a high tumor delivery of liposomal and nanoparticle agents, and generate administration schedules to enhance selective tumor uptake.

核心 1：分析和药代动力学核心 PI：William Zamboni，药剂师。博士、博士William Zamboni 是埃谢尔曼药学院的副教授。他是北卡罗来纳大学实验治疗中心 GLP 分析设施主任以及转化肿瘤学和纳米颗粒药物开发启动 (T0ND2I) 实验室主任。他多年来一直致力于抗癌药物的转化研究。他的研究兴趣集中在 药代动力学、药效学和药物遗传学原理在优化癌症化疗中的应用。他还在开发纳米体和纳米颗粒抗癌药物，并评估这些药物的分布与网状内皮系统之间的关系。作为这些研究的一部分，他使用微透析来评估肿瘤细胞外液的分布 抗癌剂以及影响抗癌剂的递送和去除的因素。他还开发了区分药物的非活性封装形式和活性​​释放形式的方法和技术，并正在评估来自纳米体和纳米颗粒的药代动力学和药效学配置的潜在表型探针。研究的临床相关性强调了需要用抗癌剂治疗实体瘤，这些抗癌剂具有高肿瘤递送脂质体和纳米颗粒剂的能力，并制定给药方案以增强选择性肿瘤摄取。